Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC

Clinical trial NCT03543683 · COMPLETED

Trial details

NCT number: NCT03543683
Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer Stage IIIB Non-small Cell Lung Cancer Stage IV EGFR T790M

Start date: 2018-01-01
Primary completion: 2023-01-31
Enrollment: 115

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.